Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day August 27, 2020
Alligator Bioscience (Nasdaq Stockholm: ATORX) will provide updates on its clinical drug candidates mitazalimab, ATOR-1015, and ATOR-1017 during a virtual R&D Day on August 27, 2020. Mitazalimab, targeting metastatic pancreatic cancer, will submit a Phase II clinical trial application by December 2020. Early signs of efficacy and safety were noted in prior studies. ATOR-1015 is advancing to Phase Ib studies for malignant melanoma with encouraging tolerability data. ATOR-1017 is in a Phase I study to activate T-cells for cancer treatment. Further details will be shared at the R&D Day.
- Mitazalimab's Phase I data shows safety and early efficacy signals, including a partial response in renal cell cancer.
- ATOR-1015's positive tolerability and ongoing dose escalation indicate strong potential for upcoming Phase Ib studies.
- ATOR-1017's unique profile could enhance immune response while minimizing side effects, supporting its Phase I development.
- Mitazalimab's next Phase II trial application is contingent on successful completion of required milestones by December 2020, posing potential delays.
- The reliance on initial efficacy readouts from ATOR-1015's Phase Ib study may introduce market volatility based on results.
LUND, Sweden, Aug. 25, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) will give status updates and details on the recent clinical development plans for the clinical drug candidates mitazalimab, ATOR-1015 and ATOR-1017 on a virtual R&D Day on August 27.
"These clinical plans provide an excellent opportunity for Alligator to have two or even three competitive cancer therapeutics in clinical efficacy studies by the end of 2021", commented Per Norlén, CEO of Alligator Bioscience.
Mitazalimab is Alligator's most advanced immunotherapy candidate intended for the treatment of different types of cancer. It activates CD40, a receptor on the dendritic cells which allows the immune system to selectively attack the cancer.
Next step in the development of mitazalimab is the submission of a Phase II clinical trial application (CTA) which is planned for December 2020. The study (OPTIMIZE-1) is an open-label, multi-center trial assessing the clinical efficacy of mitazalimab in combination with chemotherapy (mFolfirinox) in patients with metastatic pancreatic cancer. The OPTIMIZE study will be performed at several clinics in Europe, with inclusion of the first patient H1 2021.
Clinical data previously communicated from mitazalimab's Phase I development program demonstrated that mitazalimab is safe and tolerated at clinically relevant dose levels, with early signs of clinical activity identified, including a partial response in a patient with renal cell cancer and prolonged stable disease ≥6 months in 10 patients. There is still one patient in the Phase I study, now treated with mitazalimab for more than 30 months.
ATOR-1015, wholly owned by Alligator, is a tumor-localizing, bispecific CTLA-4 and OX40 antibody developed for treatment of metastatic cancer. The first indication will be skin cancer (malignant melanoma) where the target molecule CTLA-4 has been proven effective but associated with significant toxicity.
Promising data from the ongoing ATOR-1015 Phase I clinical trial was presented in June 2020 and dose escalation has continued at high doses. The positive tolerability profile of ATOR-1015 has led to the frontloading of a Phase Ib study for demonstration of single-agent activity. This allows for an efficacy readout as early as H2 2021 in malignant melanoma. This could significantly increase the value of the concept and will be followed by a Phase II combination study with anti-PD-1.
The interim data include doses up to 600 mg (about 10 mg/kg) and show that ATOR-1015 is well tolerated, thus supporting for the concept. Dose-escalation is currently at 750 mg (12.5 mg/kg). The drug related adverse events in the study have generally been mild and transient. No dose-limiting toxicity or severe immune-related adverse events have been reported.
ATOR-1017 is Alligator's wholly owned 4-1BB antibody in clinical Phase I development for the treatment of metastatic cancer. ATOR-1017 activates 4-1BB receptors on T cells which increases the ability of the immune system to detect and kill tumor cells. ATOR-1017 has a unique profile which creates an opportunity for a strong and tumor-directed immune activation that can increase efficacy and reduce side effects for the patient.
The ongoing Phase I study is a dose escalation study in patients with advanced cancer. The study is conducted at three different clinics in Sweden and is planned to include up to 50 patients. The objectives of the study are to assess the safety and tolerability of ATOR-1017, to determine the recommended dose for the subsequent Phase II studies, but also to assess initial signs of efficacy.
A more detailed invitation to the R&D Day on August 27 will be distributed shortly.
For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com
This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11:00 a.m. CEST on August 25, 2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes six lead clinical and preclinical drug candidates: Mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit www.alligatorbioscience.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day August 27, 2020 |
View original content:http://www.prnewswire.com/news-releases/alligator-bioscience-presents-the-clinical-project-portfolio-at-virtual-rd-day-august-27-2020-301117660.html
SOURCE Alligator Bioscience
FAQ
What updates will Alligator Bioscience provide on August 27, 2020?
What is the clinical focus of mitazalimab?
When is the Phase II trial application for mitazalimab expected?
What is the expected outcome of the ATOR-1015 study?
What is the target molecule for ATOR-1015?
